Daniel Mullins, PhD: How Biosimilars Are Impacting Costs

Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, discusses how biosimilars are impacting the cost of care. 
June 05, 2019


Biosimilars are a real game-changer. In the same way that we've seen a reduction in price as we see traditional medicines going to branded, we're seeing the same thing with biosimilars.

If you would have asked me what am I potentially worried about, if you look back to the literature, when generics first came out to the market in the more expedited role, there was a generic drug scandal, and if anything were to happen where there were a biosimilar that was used that we found out really wasn't as good as the originator biologic, that could set biologics back.

But short of that, I really do believe that this is going to be good for the American public.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.